GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (NAS:DBVT) » Definitions » Cyclically Adjusted PB Ratio

DBVT (DBV Technologies) Cyclically Adjusted PB Ratio : 0.37 (As of May. 30, 2025)


View and export this data going back to 2014. Start your Free Trial

What is DBV Technologies Cyclically Adjusted PB Ratio?

As of today (2025-05-30), DBV Technologies's current share price is $8.81. DBV Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $24.05. DBV Technologies's Cyclically Adjusted PB Ratio for today is 0.37.

The historical rank and industry rank for DBV Technologies's Cyclically Adjusted PB Ratio or its related term are showing as below:

DBVT' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.41
Current: 0.41

During the past years, DBV Technologies's highest Cyclically Adjusted PB Ratio was 0.41. The lowest was 0.00. And the median was 0.00.

DBVT's Cyclically Adjusted PB Ratio is ranked better than
74.63% of 670 companies
in the Biotechnology industry
Industry Median: 1.485 vs DBVT: 0.41

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

DBV Technologies's adjusted book value per share data for the three months ended in Mar. 2025 was $0.140. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $24.05 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


DBV Technologies Cyclically Adjusted PB Ratio Historical Data

The historical data trend for DBV Technologies's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DBV Technologies Cyclically Adjusted PB Ratio Chart

DBV Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

DBV Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.28

Competitive Comparison of DBV Technologies's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, DBV Technologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DBV Technologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, DBV Technologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where DBV Technologies's Cyclically Adjusted PB Ratio falls into.


;
;

DBV Technologies Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

DBV Technologies's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=8.81/24.05
=0.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DBV Technologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, DBV Technologies's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.14/120.3800*120.3800
=0.140

Current CPI (Mar. 2025) = 120.3800.

DBV Technologies Quarterly Data

Book Value per Share CPI Adj_Book
201112 5.664 97.800 6.972
201206 21.170 98.780 25.799
201212 19.317 99.100 23.465
201306 16.233 99.700 19.600
201312 18.482 99.800 22.293
201406 13.914 100.180 16.720
201412 36.634 99.860 44.162
201506 30.133 100.440 36.115
201512 72.739 100.040 87.528
201606 66.747 100.630 79.847
201612 51.817 100.650 61.974
201706 44.378 101.320 52.726
201712 31.193 101.850 36.868
201806 39.515 103.370 46.017
201809 0.000 103.560 0.000
201812 23.035 103.470 26.800
201906 18.306 104.580 21.072
201909 13.001 104.500 14.977
201912 20.539 104.980 23.552
202003 0.000 104.590 0.000
202006 22.980 104.790 26.399
202009 0.000 104.550 0.000
202012 18.741 104.960 21.494
202103 15.415 105.750 17.548
202106 13.017 106.340 14.736
202109 10.639 106.810 11.991
202112 9.035 107.850 10.085
202203 7.467 110.490 8.135
202206 13.013 112.550 13.918
202209 11.293 112.740 12.058
202212 10.345 114.160 10.909
202303 9.527 116.790 9.820
202306 8.545 117.650 8.743
202309 7.493 118.260 7.627
202312 7.285 118.390 7.407
202403 5.805 119.470 5.849
202406 4.111 120.200 4.117
202409 2.808 119.560 2.827
202412 1.335 119.950 1.340
202503 0.140 120.380 0.140

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


DBV Technologies  (NAS:DBVT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


DBV Technologies Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of DBV Technologies's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


DBV Technologies Business Description

Traded in Other Exchanges
Address
107 Avenue de la Republique, Batiment IRO, Chatillon, Paris, FRA, 92320
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
Executives
Pharis Mohideen officer: Chief Medical Officer C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451
Daniel Tasse director, officer: Chief Executive Officer C/O IKARIA, INC., 6 STATE ROUTE 173, CLINTON NJ 08809
Adora Ndu director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Virginie Boucinha officer: Chief Financial Officer C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Timothy E Morris director ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Daniel B Soland director 4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Daniele Guyot-caparros director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Madduri Ravin Rao director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, #250, AUSTIN TX 78746
Michael Goller director C/O BAKER BROTHERS INVESTMENTS, 667 MADISON AVENUE, 21ST FLOOR, NEW YORK NY 10065
Rosen Michel De director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341